Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avian Flu Drug Zanamivir Clears SFDA For Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

A bird flu drug developed by Shanghai Institute of Materia Medica, Nanjing Xian Sheng Dong Yuan Pharmaceutical and Nanjing Yifang Center for Pharmaceutical R&D have passed preclinical appraisal of China's State FDA Center for Drug Evaluation. The zanamivir capsule and its raw material drug received SFDA's approval Nov. 7 to enter clinical trials. Zanamivir, a neuraminidase inhibitor for the treatment of influenza caused by type A virus, is the second most effective avian flu drug after oseltamivir. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts